Wave Logo with Swoosh_R.jpg
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 22, 2023 07:30 ET | Wave Life Sciences USA, Inc.
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic          Extended...
2023 MDA Legacy Award for Achievement in Clinical Research
Muscular Dystrophy Association Announces Recipient of 2023 MDA Legacy Award for Achievement in Clinical Research is Merit Cudkowicz, MD, MSC, Renowned Neurologist and Clinical Researcher in ALS
March 06, 2023 09:00 ET | Muscular Dystrophy Association
New York, NY, March 06, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Merit Cudkowicz, MD, MSC, a renowned neurologist and clinical researcher in ALS (amyotrophic...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
March 06, 2023 07:00 ET | Athira Pharma, Inc.
BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
RactigenLogo.png
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
March 03, 2023 09:00 ET | Ractigen Therapeutics
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA...
MDA Advocacy Collaboration Grants Announced
Muscular Dystrophy Association Announces Five Recipient Organizations of Advocacy Collaboration Grants
February 16, 2023 09:00 ET | Muscular Dystrophy Association
New York, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the five organizations receiving $109,065 in grant funding. The grants will promote and...
MDA Shamrocks
Muscular Dystrophy Association and Buffalo Bills Running Back Nyheim Hines Launch Nation's Largest St. Patrick’s Day Fundraising Campaign
February 15, 2023 09:00 ET | Muscular Dystrophy Association
New York, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched the nation's largest St. Patrick's Day fundraising campaign, MDA Shamrocks. Thousands of...
clene-logo@2x.png
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
February 13, 2023 07:00 ET | Clene Inc.
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...
eledon-logo-1230.png
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
February 08, 2023 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the...
logo.jpg
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 07, 2023 07:00 ET | AC Immune SA
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer...
Logo-uniQure-MS-Word_Orange.jpg
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
January 31, 2023 07:05 ET | uniQure Inc.
 ~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS...